VIRADAPT

VIRADAPT

AIDS A French study of AIDS Pts unresponsive to protease inhibitors. See Genotype testing.
Mentioned in ?
References in periodicals archive ?
Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.
Drug-resistance genotyping in HIV 1 therapy: the VIRADAPT randomised controlled trial.
The VIRADAPT study was a prospective, open, randomized, and controlled study of individuals with HIV-1 infection for whom combination therapy failed (9).
Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT study.
The guidelines support 2 prospective studies reported last year (VIRADAPT and GART), whose results indicated that a significant decrease in HIV viral load could be achieved if genotypic testing were used to aid in selection of drug therapy.
Patients not in the control arm exhibited substantial improvements after receiving treatment based on the results from genotyping using VIRADAPT. The results have demonstrated that from this study and the GART study, HIV genotyping can be a useful tool in the treatment of HIV patients.